Epilepsy surgery
Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S
Record ID 32005000619
Spanish
Authors' objectives:
This study aims to summarise the available evidence on epilepsy surgery.
Authors' results and conclusions:
In adequately selected patients, these techniques may result in that 60 to 70% of patients are seizure-free for a period of 1 to 2 years of follow-up. The corpus callosotomy is a palliative technique studied in patients with disabling and drug-resistant secondary generalized seizures. In general, outcomes are poor. Only 6-7% of patients are seizure-free at 1-2 years. Hemispherectomy has been studied in cases of drug-resistant unilateral epilepsy associated to extended hemisphere lesions and deep neurological defects (Rasmussen s encephalitis, Sturge Weber s syndrome, hemimegaloencephaly).
Authors' recommendations:
It is important to point out that, in general, reports come from state-of-the-art centers with wide experience in this surgical field. On the other hand, these procedures are not adverse-event-free, in many cases severe and disabling; consequently, patient selection should be carefully carried out once more conservative therapeutic approaches have been ruled out. There is still not enough literature about the quality of life in these patients or about their long-term evolution.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.iecs.org.ar/
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Recurrence
- Treatment Outcome
- Corpus Callosum
- Epilepsy
- Neurosurgical Procedures
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.